Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck
This study has been withdrawn prior to enrollment.
Information provided by:
First received: October 4, 2005
Last updated: January 25, 2011
Last verified: January 2011
The aim of the study is to determine if Iressa added to radiotherapy is effective and safe in shrinking tumour dimensions.
Head and Neck Cancer
Carcinoma, Squamous Cell
Drug: Iressa (Gefitinib)
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A 2 Part Phase 2 Trial to Evaluate ZD1839 (Iressa™) & Radiotherapy in Patients w/Locally Advanced Inoperable Squamous Cell Carcinoma of the Head & Neck|
Resource links provided by NLM:
Genetic and Rare Diseases Information Center resources: Squamous Cell Carcinoma of the Head and NeckU.S. FDA Resources
Further study details as provided by AstraZeneca:
Primary Outcome Measures:
- Tumour Response Rate, as complete response (CR) and partial response (PR) . Six months after Last Patient In.
Secondary Outcome Measures:
- Time to progression, Overall survival, Duration of response. Six months after Last Patient In.
|Study Start Date:||July 2003|
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00233636
Sponsors and Collaborators
|Study Director:||AstraZeneca Italy Medical Director, MD||AstraZeneca|